S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

from OncLive® On Air · host OncLive® On Air

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

Episode metadata supplied by the publisher feed · Published Jul 3, 2023

Embed this episode

Attribution link and audio player

Ready to play

S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

0:00 12:56

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 12 minutes long.

When was this OncLive® On Air episode published?

This episode was published on July 3, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!